Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Keytruda Claims Market Leadership In First-line Lung Cancer

Jul 30 2017

• By Emily Hayes

3d illustration of T cells or cancer cells

Related Content

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Jun 28 2017

FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies

Jul 06 2017

MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Jul 27 2017

Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer

Jul 28 2017

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck

Jul 27 2017

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Jul 25 2017

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

AstraZeneca PLC

Merck & Co., Inc.

Pfizer Inc.

Additional Topics

Sales & Earnings Business Strategies ImmunoOncology Research & Development Cancer BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window